Vaccine Stocks Rise: Moderna and Novavax Post Double-Digit Gains

NEW YORK — Shares of leading vaccine developers Moderna Inc. (NASDAQ:MRNA) and Novavax Inc. (NASDAQ:NVAX) posted notable double-digit gains on Friday, with Moderna rising 14.21% to US$225.00 and Novavax climbing 15.80% to US$12.75. BioNTech SE (NASDAQ:BNTX) also recorded a more modest gain, up 5.32% to US$96.96. These moves underscore shifting investor focus within the vaccine sector as companies expand product portfolios amid ongoing public health demands.

The market reaction reflects growing institutional attention to vaccine manufacturers that have diversified beyond COVID-19, capturing opportunities presented by seasonal respiratory illnesses and emerging viral threats. Moderna’s recent Food and Drug Administration (FDA) approval for its mFLUSIVA influenza vaccine, designed for adults aged 50 and older, adds a significant element to its current commercial positioning. This mRNA-based flu vaccine represents Moderna’s fifth globally approved product and its fourth under FDA endorsement, marking a strategic pivot toward a broader respiratory vaccine portfolio. The company expects availability of mFLUSIVA for the 2026–2027 respiratory season alongside its established COVID-19 vaccines Spikevax and mNEXSPIKE, as well as the RSV vaccine mRESVIA. While mFLUSIVA’s accelerated approval for the 65-plus age group was based on immune response data pending confirmatory clinical benefit studies, this milestone nevertheless emphasizes Moderna’s intent to leverage mRNA technology beyond the pandemic.

Novavax’s rally similarly highlights investor engagement with firms advancing next-generation respiratory vaccine strategies but through distinct technological and commercial approaches. Its protein-based, non-mRNA COVID-19 vaccine Nuvaxovid recently received approvals in the U.S., European Union and Japan for the 2026–2027 vaccination season. Notably, these approvals support potential royalty revenues as major pharmaceutical partners Sanofi and Takeda lead commercialisation efforts in key markets. This partnership-driven model positions Novavax differently from Moderna’s direct commercial execution, underlining a diverse landscape in vaccine industry business models and investor appeal. The Matrix-M adjuvant technology embedded in Nuvaxovid continues to attract attention for its established role in shaping immune responses, providing a complementary platform alongside mRNA solutions.

This sector momentum occurs as the broader macroeconomic environment grapples with a mix of ongoing pandemic-related uncertainties, inflation pressures and geopolitical tensions influencing healthcare capital flows. Vaccine stocks like Moderna and Novavax have benefited from renewed institutional positioning focused on companies with resilient revenue streams, innovative product pipelines and global regulatory endorsements. The influenza and COVID-19 combination vaccine segments represent substantial market opportunities driven by ageing populations and heightened awareness of respiratory disease prevention. Consequently, investor sentiment increasingly favours ripple effects within biotech, where technology convergence and commercial partnerships converge to shape product lifecycle strategies.

BioNTech’s more modest share price move offers additional context within this grouping. While BNTX remains a prominent COVID-19 vaccine developer, its absence of recent high-profile respiratory vaccine updates amid this snapshot’s comparator set highlights uneven institutional capital rotation within the sector. This divergence contributes to more nuanced portfolio repositioning among biotech investors seeking differentiated exposure.

Company	Ticker	Snapshot price (USD)	Change
Moderna Inc.	NASDAQ:MRNA	$225.00	+14.21%
Novavax Inc.	NASDAQ:NVAX	$12.75	+15.80%
BioNTech SE	NASDAQ:BNTX	$96.96	+5.32%

Data Source: Yahoo Finance snapshot-15mins delayed.

While the August FDA approval of Moderna’s mFLUSIVA and Novavax’s 2026–2027 vaccination season authorisations provide important historical context, these developments serve more as business foundation pillars than direct catalysts for Friday’s share price movements. They highlight each company’s ongoing product evolution in a competitive, high-stakes environment where institutional investors weigh pipeline sustainability alongside partnership execution and regulatory advancements.

Looking ahead, Moderna and Novavax’s divergent technological platforms—mRNA versus protein-adjuvant—and their differing market strategies position them to capitalise on evolving respiratory vaccine demand well beyond COVID-19’s immediate impacts. Institutional investors will likely continue monitoring trial readouts, regulatory signals, and partner sales trajectories to gauge relative strength in this critical growth segment underpinning broader biotech rotation themes.

Spotate NewsDesk